x
For Healthcare Professionals Only

PRESCRIBING INFORMATION

Alphabetical by Janssen brand name

CILEST® 35 / 250 micrograms film-coated tablets Tablets

ACTIVE INGREDIENT(s): 0.035 mg ethinylestradiol and 0.25 mg norgestimate

Click to view CILEST® prescribing information

CONCERTA® XL 18mg, 27mg, 36mg and 54mg Prolonged Release Tablets

ACTIVE INGREDIENT(s): methylphenidate hydrochloride

Click to view CONCERTA® XL prescribing information

DAKTACORTTM 2% / 1% w/w ointment

ACTIVE INGREDIENT(s): Miconazole nitrate 2% w/w and hydrocortisone 1% w/w

Click to view DAKTACORTTM prescribing information

DARZALEX® 20 MG/ML concentrate for solution for infusion

ACTIVE INGREDIENT(s): Daratumumab

Click to view DARZALEX® prescribing information

DUROGESIC® DTRANS® 12/25/50/75/100 mcg/hr transdermal patch

ACTIVE INGREDIENT(s): fentanyl

Click to view DUROGESIC® DTRANS® prescribing information

EDURANT® 25 mg film-coated tablet

ACTIVE INGREDIENT(s): rilpivirine

Click to view EDURANT® prescribing information

EVRA® 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch

ACTIVE INGREDIENT(s): norelgestromin and ethinyl estradiol

Click to view EVRA® prescribing information

HALDOL® decanoate 50 mg/ml and 100 mg/ml

ACTIVE INGREDIENT(s): Haloperidol decanoate

Click to view HALDOL® decanoate prescribing information

HALDOL® 2 mg/ml oral solution

ACTIVE INGREDIENT(s): Haloperidol

Click to view HALDOL® 2 mg/ml oral solution prescribing information

IMBRUVICA® 140mg Hard Capsules

ACTIVE INGREDIENT(s): ibrutinib

Click to view IMBRUVICA® prescribing information

INTELENCE® 25 mg, 100 mg & 200 mg tablets

ACTIVE INGREDIENT(s): etravirine

Click to view INTELENCE® prescribing information

INVEGA® 3 mg, 6 mg and 9 mg prolonged release tablets

ACTIVE INGREDIENT(s): paliperidone

Click to view INVEGA® prescribing information

INVOKANA® 100mg and 300mg film-coated tablets

ACTIVE INGREDIENT(s): canagliflozin

Click to view INVOKANA® prescribing information

PREZISTA® 100mg/ml oral suspension and 75mg, 150mg, 400mg, 600mg and 800mg film-coated tablets

ACTIVE INGREDIENT(s): darunavir

Click to view PREZISTA® prescribing information

REZOLSTA® 800 mg/150 mg film-coated tablets

ACTIVE INGREDIENT(s): Darunavir and cobicistat

Click to view REZOLSTA® prescribing information

RISPERDAL® CONSTA® 25mg, 37.5mg and 50mg injection

ACTIVE INGREDIENT(s): risperidone

Click to view Risperdal®Consta® prescribing information

RISPERDAL® Film-Coated Tablets, Oral Solution and Risperdal® Quicklet® Orodispersible Tablets

ACTIVE INGREDIENT(s): risperidone

Click to view RISPERDAL® Film-Coated Tablets, Oral Solution and Risperdal® Quicklet® Orodispersible Tablets prescribing information

STELARA® solution for injection

ACTIVE INGREDIENT(s): ustekinumab

Click to view STELARA® prescribing information

SYLVANT® 100 mg and 400mg powder for concentrate for solution for infusion

ACTIVE INGREDIENT(s): siltuximab

Click to view SYLVANT® prescribing information

SYMTUZA® 800 mg/150 mg/200 mg/10 mg film coated tablets

ACTIVE INGREDIENT(s): darunavir, cobicistat, emtricitabine, tenofovir alafenamide

Click to view SYMTUZA® prescribing information

TREVICTA® 175 mg, 263 mg, 350 mg & 525 mg prolonged release suspension for injection

ACTIVE INGREDIENT(s): 175 mg, 263 mg, 350 mg & 525 mg paliperidone

Click to view TREVICTA® prescribing information

VELCADE® 3.5 mg powder for solution for injection

ACTIVE INGREDIENT(s): bortezomib

Click to view VELCADE® prescribing information

VOKANAMET® 50mg/850mg and 50/1000mg film-coated tablets

ACTIVE INGREDIENT(s): canagliflozin and metformin hydrochloride

Click to view VOKANAMET® prescribing information

XEPLION® 50 mg, 75 mg, 100 mg & 150 mg prolonged release suspension for injection

ACTIVE INGREDIENT(s): paliperidone

Click to view XEPLION® prescribing information

ZYTIGA® 500 mg film-coated tablets

ACTIVE INGREDIENT(s): abiraterone acetate

Click to view ZYTIGA® prescribing information

 

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse reactions related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Limited on 01494 567447 or at dsafety@its.jnj.com.